|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.78 USD | -0.41% |
|
-0.68% | -0.11% |
| 14/01 | Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating | MT |
| 13/01 | Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM |
Company Valuation: Exelixis, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,227 | 5,784 | 5,174 | 7,460 | 9,510 | 11,786 | 11,786 | - |
| Change | - | -7.11% | -10.54% | 44.19% | 27.47% | 23.93% | 0% | - |
| Enterprise Value (EV) 1 | 5,020 | 4,317 | 3,865 | 6,465 | 8,399 | 11,206 | 10,681 | 9,662 |
| Change | - | -14.01% | -10.45% | 67.25% | 29.91% | 33.43% | -4.68% | -9.55% |
| P/E ratio | 57.3x | 25.4x | 28.6x | 36.9x | 18.9x | 16.7x | 14.2x | 11.1x |
| PBR | 3.4x | 2.64x | 2.09x | 3.21x | 4.18x | 4.51x | 3.35x | 2.63x |
| PEG | - | 0x | -1.3x | 2.3x | 0x | 0.3x | 0.8x | 0.4x |
| Capitalization / Revenue | 6.31x | 4.03x | 3.21x | 4.08x | 4.39x | 5.06x | 4.54x | 3.9x |
| EV / Revenue | 5.08x | 3.01x | 2.4x | 3.53x | 3.87x | 4.81x | 4.11x | 3.19x |
| EV / EBITDA | 42.1x | 14.4x | 17.4x | 32.9x | 13.3x | 11.8x | 10.8x | 7.91x |
| EV / EBIT | 45.6x | 15.1x | 19.2x | 37.8x | 13.9x | 13.1x | 10.6x | 7.6x |
| EV / FCF | 28.1x | 12.8x | 17.2x | 22.1x | 12.5x | 18.4x | 13.4x | 9.31x |
| FCF Yield | 3.56% | 7.8% | 5.8% | 4.53% | 8% | 5.43% | 7.48% | 10.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.35 | 0.72 | 0.56 | 0.65 | 1.76 | 2.615 | 3.076 | 3.929 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 987.5 | 1,435 | 1,611 | 1,830 | 2,169 | 2,327 | 2,597 | 3,025 |
| EBITDA 1 | 119.2 | 300.3 | 222.4 | 196.6 | 633.4 | 947.2 | 986.6 | 1,221 |
| EBIT 1 | 110.1 | 286.7 | 201.5 | 170.9 | 604.6 | 853.9 | 1,004 | 1,272 |
| Net income 1 | 111.8 | 231.1 | 182.3 | 207.8 | 521.3 | 734 | 821.8 | 1,040 |
| Net Debt 1 | -1,207 | -1,467 | -1,308 | -995.3 | -1,111 | -579.5 | -1,104 | -2,124 |
| Reference price 2 | 20.07 | 18.28 | 16.04 | 23.99 | 33.30 | 43.78 | 43.78 | 43.78 |
| Nbr of stocks (in thousands) | 3,10,244 | 3,16,397 | 3,22,561 | 3,10,974 | 2,85,579 | 2,69,203 | 2,69,203 | - |
| Announcement Date | 10/02/21 | 17/02/22 | 07/02/23 | 06/02/24 | 11/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.81x | 4.84x | 11.88x | -.--% | 1.18TCr | |
| 44.76x | 10.62x | 38.01x | 0.02% | 4.8TCr | |
| 17.74x | 6.36x | 13.98x | 1.64% | 4.38TCr | |
| -27.29x | 59.81x | -30.05x | -.--% | 3.44TCr | |
| -27.62x | 4.82x | -13.15x | -.--% | 2.74TCr | |
| 31.31x | 6.18x | 17.12x | -.--% | 2.01TCr | |
| 17.27x | 4.37x | 11.58x | -.--% | 1.96TCr | |
| -407.05x | 27.88x | 658.11x | -.--% | 1.39TCr | |
| -194.83x | 46.29x | -187.55x | -.--% | 1.34TCr | |
| -13.14x | 165.06x | -25.74x | -.--% | 1.31TCr | |
| Average | -54.20x | 33.62x | 49.42x | 0.17% | 2.46TCr | |
| Weighted average by Cap. | -24.55x | 26.16x | 32.68x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- EXEL Stock
- Valuation Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition